---
title: "Hester Biosciences Ltd (HESTERBIO) — Share Price, Financials & Analysis"
symbol: "HESTERBIO"
company: "Hester Biosciences Ltd"
canonical: "https://tapetide.com/stocks/HESTERBIO"
isin: "INE782E01017"
nse_symbol: "HESTERBIO"
bse_code: "524669"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 1940.76
generated_at: "2026-09-13T18:39:31.617Z"
---

# Hester Biosciences Ltd (HESTERBIO)

Canonical page: https://tapetide.com/stocks/HESTERBIO

## Company

- **NSE Symbol:** HESTERBIO
- **BSE Code:** 524669
- **ISIN:** INE782E01017
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2015-03-13
- **CEO:** Mr. Rajiv Dinesh Gandhi B.Com
- **Employees:** 562
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** hester.in

## About

Incorporated in 1987, Hester Biosciences Ltd is one of India’s leading animal healthcare companies and a major manufacturer of poultry and animal vaccines, including a leading position in PPR and Goat Pox vaccines.[1]

## Latest Price

- **Price:** ₹2264.9
- **Change:** -14.1 (-0.62%)
- **Open:** ₹2275
- **Day High:** ₹2298.9
- **Day Low:** ₹2238.3
- **Previous Close:** ₹2279
- **Volume:** 5276
- **As Of:** 2026-09-11T10:29:01+00:00

## Key Fundamentals

Observed at 2026-09-11T04:47:20.265536Z.

- **Market Cap:** ₹1940.76 Cr
- **Classification:** Microcap
- **P/E (reported):** 14.3
- **P/E (TTM):** 14.15
- **EPS (TTM):** ₹160.08
- **EPS (reported):** ₹22.75
- **Book Value:** ₹423.46
- **Price to Book:** 5.43
- **Dividend Yield:** 0.48%
- **ROE:** 15.63%
- **ROCE:** 16.51%
- **Debt to Equity:** 0.54
- **Revenue (yearly):** ₹342.3 Cr
- **Net Income:** ₹57.5 Cr
- **EBITDA:** ₹96.3 Cr
- **52-Week High:** ₹2683.6
- **52-Week Low:** ₹1239.3
- **RSI (14):** 45.11

## Tapetide Score

- **Score:** 58 / 100
- **Score date:** 2026-09-04
- **Archetype:** Quality at a Reasonable Price
- **What it means:** Financial strength is not being paid for with a demanding multiple. The question worth asking is whether the quality is durable or reflects a good patch — check the consistency of returns over several years rather than the latest quarter.
- **Pillar profile:** Quality: Good · Valuation: Cheap · Momentum: Rising
- **Percentile:** 81.3 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 47.22 | 9% |
| growth | 19.07 | 9% |
| momentum | 82.73 | 12% |
| ownership | 43.96 | 24% |
| quality | 61.84 | 22% |
| valuation | 76.08 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has been maintaining a healthy dividend payout of 21.8%
- Company's working capital requirements have reduced from 80.2 days to 54.4 days

### Weaknesses

- Stock is trading at 5.35 times its book value
- The company has delivered a poor sales growth of 9.19% over past five years.
- Company has a low return on equity of 10.8% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.105 Cr.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -0.57% | 33.13% | 636.39% |
| ebitda margin growth | 209.7% | 36.45% | 37.99% | -5.03% |
| net income growth | 486.06% | 99.65% | 26% | 8% |
| revenue growth | 63.2% | 8.67% | 8% | 9% |
| roce | 247% | 66.77% | 77.72% | 11.51% |
| roe | 484.47% | 77.21% | 10.48% | 5.82% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 70 | 67 | 79 | 82 | 84 | 63 | 82 | 84 | 71 | 77 | 100 | 77 |
| Expenses | 57 | 57 | 63 | 65 | 65 | 58 | 63 | 61 | 59 | 60 | 66 | 54 |
| Operating Profit | 13 | 10 | 16 | 18 | 19 | 5 | 19 | 23 | 12 | 18 | 34 | 23 |
| OPM % | 19 | 15 | 20 | 21 | 23 | 8 | 23 | 27 | 17 | 23 | 34 | 29 |
| Other Income | 6 | 2 | 5 | 2 | 3 | 9 | -6 | 3 | 12 | 2 | 2 | 89 |
| Interest | 8 | 2 | 7 | 5 | 6 | -4 | 6 | 2 | 2 | 2 | 5 | 3 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 6 | 7 |
| Profit before tax | 7 | 6 | 10 | 11 | 12 | 13 | 4 | 20 | 17 | 14 | 25 | 102 |
| Tax % | 40 | 37 | 35 | 29 | 29 | 15 | 59 | 14 | 16 | 31 | 34 | 5 |
| Net Profit | 4 | 4 | 6 | 7 | 8 | 11 | 2 | 17 | 14 | 9 | 17 | 97 |
| EPS in Rs | 4.81 | 4.68 | 5.82 | 7.45 | 9.64 | 13.71 | 1.52 | 19.33 | 16.99 | 10.31 | 18.78 | 114 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 136 | 178 | 183 | 214 | 235 | 266 | 305 | 311 | 333 | 326 |
| Expenses | 89 | 110 | 128 | 146 | 175 | 215 | 251 | 250 | 246 | 239 |
| Operating Profit | 47 | 68 | 55 | 69 | 60 | 51 | 54 | 62 | 87 | 87 |
| OPM % | 35 | 38 | 30 | 32 | 26 | 19 | 18 | 20 | 26 | 27 |
| Other Income | 3 | 7 | 6 | 1 | 14 | 20 | 15 | 8 | 19 | 105 |
| Interest | 4 | 7 | 7 | 7 | 4 | 9 | 20 | 13 | 11 | 12 |
| Depreciation | 10 | 12 | 13 | 13 | 17 | 21 | 17 | 17 | 19 | 22 |
| Profit before tax | 36 | 57 | 41 | 50 | 54 | 40 | 32 | 40 | 76 | 157 |
| Tax % | 36 | 28 | 25 | 31 | 26 | 30 | 34 | 27 | 24 | — |
| Net Profit | 23 | 41 | 31 | 35 | 39 | 28 | 21 | 29 | 57 | 137 |
| EPS in Rs | 30.12 | 48.87 | 34.29 | 40.47 | 46.22 | 31.3 | 22.21 | 32.31 | 65.41 | 160.08 |
| Dividend Payout % | 33 | 23 | 19 | 25 | 22 | 26 | 27 | 22 | 17 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 113 | 132 | 169 | 193 | 220 | 251 | 271 | 283 | 306 | 352 |
| Borrowings | 66 | 69 | 90 | 121 | 105 | 228 | 274 | 244 | 213 | 195 |
| Other Liabilities | 25 | 35 | 32 | 65 | 78 | 74 | 116 | 126 | 126 | 123 |
| Total Liabilities | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 | 678 |
| Fixed Assets | 102 | 110 | 145 | 143 | 133 | 237 | 259 | 240 | 233 | 411 |
| CWIP | 21 | 32 | 7 | 74 | 109 | 82 | 149 | 171 | 183 | 9 |
| Investments | 0 | 0 | 0 | 0 | 0 | 21 | 25 | 30 | 34 | 43 |
| Other Assets | 89 | 102 | 148 | 170 | 169 | 222 | 237 | 221 | 203 | 215 |
| Total Assets | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 | 678 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 35 | 38 | 47 | 37 | 58 | 9 | 24 | 48 | 65 | 64 |
| Cash from Investing Activity | -30 | -26 | -21 | -73 | -42 | -117 | -77 | -22 | -20 | -18 |
| Cash from Financing Activity | 2 | -11 | 3 | 19 | -18 | 112 | 42 | -26 | -52 | -49 |
| Net Cash Flow | 6 | 1 | 28 | -17 | -2 | 3 | -12 | 0 | -7 | -3 |
| Free Cash Flow | 5 | 15 | 24 | -36 | 17 | -87 | -54 | 24 | 44 | 47 |
| CFO/OP | 102 | 100 | 92 | 86 | 105 | 43 | 63 | 112 | 123 | 90 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 79 | 87 | 67 | 116 | 84 | 86 | 109 | 94 | 86 | 105 |
| Inventory Days | 376 | 505 | 540 | 834 | 452 | 424 | 399 | 288 | 291 | 323 |
| Days Payable | 84 | 100 | 93 | 261 | 204 | 101 | 141 | 98 | 122 | 110 |
| Cash Conversion Cycle | 371 | 491 | 514 | 690 | 332 | 409 | 367 | 284 | 255 | 318 |
| Working Capital Days | 90 | 82 | 106 | 104 | 134 | 113 | 88 | 112 | 74 | 54 |
| ROCE % | 19 | 20 | 26 | 16 | 18 | 14 | 9 | 9 | 10 | 15 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% |
| FIIs | 0% | 0% | 0.43% | 0.52% | 0.61% | 0.59% | 0.87% | 0.52% | 0.53% | 0.51% | 0.38% | 0.31% |
| DIIs | 0% | 0% | 0% | 0% | 0.02% | 0.02% | 0.02% | 0.02% | 0% | 0.01% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 33.19% | 33.3% | 33.32% | 32.63% | 32.67% | 32.68% | 32.64% | 32.8% | 32.92% | 33.06% | 33.29% | 33% |
| Others | 13.08% | 12.96% | 12.52% | 13.12% | 12.97% | 12.97% | 12.73% | 12.93% | 12.82% | 12.68% | 12.6% | 12.95% |
| No. of Shareholders | 13342 | 13450 | 12844 | 11305 | 11538 | 11473 | 11853 | 11810 | 12260 | 12603 | 12373 | 11961 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 5 / 6 / 8

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 2279.05 | Sell |
| EMA (10) | 2300.64 | Sell |
| SMA (20) | 2329.27 | Sell |
| EMA (20) | 2324.22 | Sell |
| SMA (50) | 2373.88 | Sell |
| EMA (50) | 2300.53 | Sell |
| SMA (100) | 2135.83 | Buy |
| EMA (100) | 2157.86 | Buy |
| SMA (200) | 1827.32 | Buy |
| EMA (200) | 1983.22 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 44.05 | Neutral |
| MACD (12,26,9) | -25.74 | Sell |
| Stochastic (14,3,3) | 36.17 | Neutral |
| ADX (14) | 26.14 | Buy |
| Williams %R (14) | -69.89 | Neutral |
| ATR (14) | 94.28 | High Volatility |
| ROC (12) | -3.8 | Sell |
| Stoch RSI (14) | 50.91 | Neutral |
| UO (7,14,28) | 48.11 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-04 | [Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38fd4522-5647-4ffc-b1be-c301a6cf0e0e.pdf) |
| 2026-09-04 | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c58fd623-8921-4192-8ae2-9e34eaa27089.pdf) |
| 2026-09-04 | [Shareholders Approval For Reclassification From Promoter And Promoter Group Category To Public Category Shareholders](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cf6db54c-9645-4564-8610-eb5ab7f2fe94.pdf) |
| 2026-08-27 | [Announcement under Regulation 30 (LODR)-Credit Rating](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d4fddb59-6f1a-435c-b4bb-693bdff0363b.pdf) |
| 2026-08-04 | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=18f8ae3f-3dbc-459b-9568-b21cbff51eda.pdf) |
| 2026-08-01 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c74d406-d25d-44cc-8440-7aa8af888933.pdf) |
| 2026-07-31 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e16730c2-c842-4b81-8b0a-0f79fe382921.pdf) |
| 2026-07-31 | [Launch Of Interactive Microsite Of 39Th Annual Report FY 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e45013c-dc78-42a7-8c73-a55385e9fdd5.pdf) |
| 2026-07-30 | [Board Meeting Outcome for Outcome Of Board Meeting Held On 30 July 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=524b146c-5f44-4a31-830d-5731827de593.pdf) |
| 2026-07-30 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69676eea-9729-4651-9537-d562ccf4acee.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-30 | [Financial Results For The Quarter Ended 30 June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b1dc977e-f7df-45e0-a0e4-1091424c8c6a.pdf) |
| 2026-05-15 | [Financial Results For The Quarter And Year Ended 31 March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2a58da5-fee8-4436-a33f-9e5a44950eeb.pdf) |
| 2026-01-30 | [Financial Results For The Period Ended 31 December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac345075-7540-4502-a7e8-4a24290613f1.pdf) |
| 2025-11-12 | [Financial Results For The Period Ended 30 September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2fb2d324-ac11-4c8c-b7ab-0920101e1b29.pdf) |
| 2025-08-01 | [Financial Results Q1 FY 2025-2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f3f0d35-8c30-41a8-b5a7-336e6270256e.pdf) |
| 2025-05-09 | [Financial Results Q4 & FY 25](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eef2489d-1b35-4042-b61a-b52877d649b6.pdf) |
| 2025-01-30 | [Financial Results For The Period Ended 31 December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a878cae7-6e2a-4ab3-a4c3-a6e4c8d563a3.pdf) |
| 2024-10-28 | [Financial Results For The Period Ended 30 September 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f1c4bcfd-44ee-4ce2-adb2-1abb1f972376.pdf) |
| 2024-08-02 | [Financial Results Q1 FY25](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b317f90b-6e6b-45ac-83d5-5297debd6d83.pdf) |
| 2024-05-10 | [Financial Results For The Period Ended Q4 & FY 2023-24](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5f8f0ee-dbd4-4613-8b11-0e49d32bf524.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-07-30 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4b277a25-df96-4173-aeba-436b39952dc6.pdf) |
| 2026-05-15 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef98000e-fedc-4806-aae8-a4fdf52baaf3.pdf) |
| 2026-01-30 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0fcebbc3-afee-4d9e-9592-25859f0662e4.pdf) |
| 2025-11-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eef02284-4cb4-4e02-8f65-481e53a6394e.pdf) |
| 2025-08-01 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef01fb78-9155-4c3e-96a9-5982a172db19.pdf) |
| 2025-05-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0153496f-f1a1-4cbb-8853-4b6ffe976750.pdf) |
| 2024-10-28 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4137e734-05ed-422f-b109-28cd515f8ded.pdf) |
| 2024-08-02 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=909cad4b-497b-4975-a71f-1e875d0bedcb.pdf) |
| 2024-05-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b5b1d2d0-bdc2-41d7-a558-be1111fdc7e1.pdf) |
| 2024-02-02 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=10e6d444-139a-4727-9905-345c9a53bef8.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=40c0fe69-5d20-4b96-ae6c-881b2aa47bd6.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/40c0fe69-5d20-4b96-ae6c-881b2aa47bd6.pdf) |
| Oct 2018 | [Concall - Oct 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=84c8c9d4-490c-4de1-8d30-4a96e8b5143c.pdf) |
| Oct 2018 | [Concall - Oct 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/10/84c8c9d4-490c-4de1-8d30-4a96e8b5143c.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b8cec2d9-c3ff-46b7-823e-bf5c6ef0df3e.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b8cec2d9-c3ff-46b7-823e-bf5c6ef0df3e.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db1d735b-cb8e-475c-ae54-b17058e14719.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/db1d735b-cb8e-475c-ae54-b17058e14719.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a164b93-4364-4314-89b6-7927763cae43.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9a164b93-4364-4314-89b6-7927763cae43.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 8 May - Board meeting on 15 May 2026 to approve FY26 audited results and consider dividend. | [Board Meeting Intimation for Financial Results And Dividend 8 May - Board meeting on 15 May 2026 to approve FY26 audited results and consider dividend.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/bb38190d-74b1-4636-9a37-c1dfeff9298d.pdf) |
| 8 Apr - Confirmation certificate for securities dematerialised/rematerialised during quarter ended 31 March 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr - Confirmation certificate for securities dematerialised/rematerialised during quarter ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/12394114-7ee8-4d73-afb7-c57c3c1408af.pdf) |
| 5 Feb - Newspaper Clippings of Postal Ballot Notice | [Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Feb - Newspaper Clippings of Postal Ballot Notice](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b5efbf91-a405-498f-9412-2b6795b4869b.pdf) |
| 3 Apr - Hester Biosciences says it is not a Large Corporate under SEBI circular. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 3 Apr - Hester Biosciences says it is not a Large Corporate under SEBI circular.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/235f64c0-a4c7-49f9-a486-972be32a78aa.pdf) |
| 26 Mar - Trading window closed from 1 April 2026 until 48 hours after FY2026 results' public release. | [Closure of Trading Window 26 Mar - Trading window closed from 1 April 2026 until 48 hours after FY2026 results' public release.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2d429966-7e35-4c9a-8991-5fe459ef3305.pdf) |
| 20 Mar - CARE downgraded Hester Biosciences' ratings on 19 Mar 2026; long-term to BBB; total facilities Rs131.47 crore. | [Announcement under Regulation 30 (LODR)-Credit Rating 20 Mar - CARE downgraded Hester Biosciences' ratings on 19 Mar 2026; long-term to BBB; total facilities Rs131.47 crore.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/50837848-af4e-4e6a-aede-15e713882b4e.pdf) |
| 11h - The Company has scheduled investor interaction through a teleconference call on Friday, 15 May 2026 at 2:00 p.m. (IST), post the announcement of financial results … | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11h - The Company has scheduled investor interaction through a teleconference call on Friday, 15 May 2026 at 2:00 p.m. (IST), post the announcement of financial results …](https://www.bseindia.com/xml-data/corpfiling/AttachLive/8744061d-1252-4fa4-be92-14491aee959e.pdf) |
| 11 Mar - Sale of 43.81% in Texas Lifesciences for INR 92 million; TLPL ceases as subsidiary; completion within three months. | [Board Meeting Outcome for Outcome Of Board Meeting 11 Mar - Sale of 43.81% in Texas Lifesciences for INR 92 million; TLPL ceases as subsidiary; completion within three months.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4af496d9-fb04-43e9-8a0b-fd83facf3888.pdf) |
| 11 Mar - Hester sells 43.81% in Texas Lifesciences to Ticop Life for INR 92 million; completion within three months, retains 11%.','checklist':['Review announcement content and extract key facts','Assess … | [Announcement under Regulation 30 (LODR)-Diversification / Disinvestment 11 Mar - Hester sells 43.81% in Texas Lifesciences to Ticop Life for INR 92 million; completion within three months, retains 11%.','checklist':['Review announcement content and extract key facts','Assess …](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e50cb418-e0e4-4788-80cf-329ae7603bc9.pdf) |
| — | [Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 10 Mar](https://www.bseindia.com/xml-data/corpfiling/AttachHis/166e3b51-da98-458d-9ec2-c3107fb5a0dc.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0bf7d42e-8e89-4ae2-b2f6-745e6b76d194.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a5850666-32d9-45ce-8b67-a2af928214d2.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0cda3171-ca19-4c9c-b310-1ce8047a0ba0.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b2ad84ad-8a59-4ed1-9971-2b1c75ba585b.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524669/73962524669.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/524669/69086524669_26_07_21.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/524669/5246690320.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/524669/5246690319.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:39:31.617Z.